NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today the launch of a new line of germline cancer predisposition testing services. The new ...
-Collaboration will leverage NeoGenomics’ large oncology diagnostic laboratory and Massive Bio’s proven-at-scale proprietary artificial intelligence platform to accelerate drug discovery and optimize ...
Neo Comprehensive™ - Heme Cancers is a large and comprehensive next-generation sequencing panel with broad coverage of genes associated with blood cancers Early-stage NSCLC Panel - a therapy selection ...
FT. MYERS, FL / ACCESSWIRE / July 27, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, announced today that the Molecular Diagnostics Services Program (MolDx) has ...
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the presentation of assay-relevant data, including interventional ...
NeoGenomics is transitioning from a commodity diagnostic provider to a comprehensive precision oncology platform. Read why ...
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of diagnostics and lab services industry veteran ...
FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NEO) (the “Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its third quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results